Literature DB >> 26994052

A case of psoriasis pustolosa palmaris induced by cetuximab.

Elena Marinello1, Davide Pastorelli2, Mauro Alaibac1.   

Abstract

Cetuximab is a monoclonal antibody that competitively inhibits the epidermal growth factor receptor (EGFR). It is used for the treatment of metastatic colorectal cancer after first-line therapy. We report the first case of a pustular psoriasiform drug eruption induced by cetuximab in a patient with colorectal cancer. This paradoxical side effect could be the result of an imbalance in downstream molecular pathways due to the EGFR signal blockade that could, in selected patients, induce alternative signalling pathways related to keratinocyte proliferation. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26994052      PMCID： PMC4800207          DOI： 10.1136/bcr-2016-214582

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  12 in total

Review 1.  Current concepts in psoriasis and its treatment.

Authors:  C O Mendonça; A D Burden
Journal:  Pharmacol Ther       Date:  2003-08       Impact factor: 12.310

2.  Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.

Authors:  Markella-Pagona Zorzou; Alexandros Stratigos; Eleni Efstathiou; Aristotle Bamias
Journal:  Acta Derm Venereol       Date:  2004       Impact factor: 4.437

3.  Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy.

Authors:  Florence Trivin; Eveline Boucher; Jean-Luc Raoul
Journal:  Acta Oncol       Date:  2004       Impact factor: 4.089

4.  Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: a potential beneficial effect on psoriasis vulgaris.

Authors:  Ken Okamoto; Hiromichi Maeda; Takeo Shiga; Mai Shiga; Ken Dabanaka; Kazuhiro Hanazaki; Michiya Kobayashi
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 5.  Epidermal growth factor receptor inhibitors: coming of age.

Authors:  Amit Mahipal; Nishi Kothari; Shilpa Gupta
Journal:  Cancer Control       Date:  2014-01       Impact factor: 3.302

6.  Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis.

Authors:  L B Nanney; C M Stoscheck; M Magid; L E King
Journal:  J Invest Dermatol       Date:  1986-03       Impact factor: 8.551

7.  Psoriasis induced by cetuximab: a paradoxical adverse effect.

Authors:  Albert Mas-Vidal; Pablo Coto-Segura; Cristina Galache-Osuna; Jorge Santos-Juanes
Journal:  Australas J Dermatol       Date:  2010-08-16       Impact factor: 2.875

8.  Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris.

Authors:  K S Anderson; S Petersson; J Wong; E Shubbar; N N Lokko; M Carlström; C Enerbäck
Journal:  Br J Dermatol       Date:  2010-11       Impact factor: 9.302

9.  EGF receptor expression and growth of psoriatic and normal human keratinocytes are modulated by 1.25 (OH)2-vitamin D3 ex vivo.

Authors:  A M Boisseau-Garsaud; P Donatien; C Margerin; A Taïeb
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

10.  Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis.

Authors:  B Neyns; V Meert; F Vandenbroucke
Journal:  Curr Oncol       Date:  2008-08       Impact factor: 3.677
View more
  1 in total

Review 1.  Recent advances on the roles of epidermal growth factor receptor in psoriasis.

Authors:  Sijia Wang; Zhuoli Zhang; Han Peng; Kang Zeng
Journal:  Am J Transl Res       Date:  2019-02-15       Impact factor: 4.060
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.